Literature DB >> 26269752

Quantitative DNA hypomethylation of ligand Jagged1 and receptor Notch1 signifies occurrence and progression of breast carcinoma.

Yuwen Cao1, Yixiao Li1, Na Zhang1, Jianming Hu1, Liang Yin2, Zemin Pan3, Yucong Li1, Xiaoming Du1, Wenjie Zhang1, Feng Li1.   

Abstract

Methylation alterations of Jagged1 and Notch1 genes have been reported in non-tumor lesions and a few cancers. However, methylation profiles of Jagged1 promoter and Notch1 exon25 in breast cancer and matched normal tissue and the association of methylation with clinicopathological characteristics still remain unclear. To explore the potential effects of aberrant DNA methylation of Jagged1 and Notch1 on occurrence and progression of breast cancer, we detected the quantitative DNA methylation of Jagged1 and Notch1 in 73 breast cancer (BC) and 20 adjacent normal breast tissues (ANBT) by using MassARRAY spectrometry. The methylation level of overall and majority individual CpG sites of the two genes were synergistically significantly lower in BC than in ANBT. The overall hypomethylation of the two genes, particularly of Jagged1 CpG_8.9.10 and Notch1 CpG_14.15.16 in primary tumors, were markedly associated with lymph node metastasis, advanced stage and high grade. The protein expressions of the both genes were examined by immunohistochemical staining in same cohorts. The expression was significantly inverse correlation with methylation. The two proteins in primary tumor were synergistically up-regulated and dramatically related to lymph node metastasis, advanced stage and high grade. Our findings suggest that the synergetic hypomethylation of Jagged1 and Notch1 genes, especially of Jagged1 CpG_8.9.10 and Notch1 CpG_14.15.16, may involve tumorigenesis and development of breast cancer. The negative relationship between methylation and expression indicates methylation role for expression regulation. The synergetic overexpression of the two proteins further indicates the effects on occurrence and progression of breast cancer.

Entities:  

Keywords:  Jagged1; Notch1; breast cancer; expression; methylation; occurrence; progression

Year:  2015        PMID: 26269752      PMCID: PMC4529612     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  38 in total

1.  Implications of the Notch1-Snail/Slug-epithelial to mesenchymal transition axis for lymph node metastasis in infiltrating ductal carcinoma.

Authors:  Yu-Wen Cao; Guo-Xing Wan; Jian-Ping Sun; Xiao-Bin Cui; Jian-Ming Hu; Wei-Hua Liang; Yu-Qin Zheng; Wen-Qin Li; Feng Li
Journal:  Kaohsiung J Med Sci       Date:  2014-12-16       Impact factor: 2.744

2.  [Detection and clinical significance of Notch1 methylation in breast cancer and intraductal proliferative breast lesions].

Authors:  Na Zhang; Zhen-zhu Sun; Feng Li; Yu-wen Cao; Chun-xia Zhao; Wei-hua Liang; Hua-peng Sun; Hong-an Li; Xin-ge Fu
Journal:  Zhonghua Bing Li Xue Za Zhi       Date:  2011-05

3.  High-level JAG1 mRNA and protein predict poor outcome in breast cancer.

Authors:  Brendan C Dickson; Anna Marie Mulligan; Hui Zhang; Gina Lockwood; Frances P O'Malley; Sean E Egan; Michael Reedijk
Journal:  Mod Pathol       Date:  2007-06       Impact factor: 7.842

4.  Epigenetic modification at Notch responsive promoters blunts efficacy of inducing notch pathway reactivation after myocardial infarction.

Authors:  Giulia Felician; Chiara Collesi; Marina Lusic; Valentina Martinelli; Matteo Dal Ferro; Lorena Zentilin; Serena Zacchigna; Mauro Giacca
Journal:  Circ Res       Date:  2014-08-11       Impact factor: 17.367

5.  Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma.

Authors:  Violetta V Leshchenko; Pei-Yu Kuo; Rita Shaknovich; David T Yang; Tobias Gellen; Adam Petrich; Yiting Yu; Yvonne Remache; Marc A Weniger; Sarwish Rafiq; K Stephen Suh; Andre Goy; Wyndham Wilson; Amit Verma; Ira Braunschweig; Natarajan Muthusamy; Brad S Kahl; John C Byrd; Adrian Wiestner; Ari Melnick; Samir Parekh
Journal:  Blood       Date:  2010-04-28       Impact factor: 22.113

6.  Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry.

Authors:  Mathias Ehrich; Matthew R Nelson; Patrick Stanssens; Marc Zabeau; Triantafillos Liloglou; George Xinarianos; Charles R Cantor; John K Field; Dirk van den Boom
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-21       Impact factor: 11.205

7.  Epigenetic mechanisms underlying arsenic-associated lung carcinogenesis.

Authors:  Simone G J van Breda; Sandra M H Claessen; Ken Lo; Marcel van Herwijnen; Karen J J Brauers; Sofia Lisanti; Daniël H J Theunissen; Danyel G J Jennen; Stan Gaj; Theo M C M de Kok; Jos C S Kleinjans
Journal:  Arch Toxicol       Date:  2014-09-09       Impact factor: 5.153

8.  Inactivation of miR-34a by aberrant CpG methylation in Kazakh patients with esophageal carcinoma.

Authors:  Xiaobin Cui; Zhimin Zhao; Dong Liu; Tao Guo; Su Li; Jianming Hu; Chunxia Liu; Lan Yang; Yuwen Cao; Jinfang Jiang; Weihua Liang; Wei Liu; Shugang Li; Lianghai Wang; Lidong Wang; Wenyi Gu; Chuanyue Wu; Yunzhao Chen; Feng Li
Journal:  J Exp Clin Cancer Res       Date:  2014-02-17

9.  Epigenomic alterations in breast carcinoma from primary tumor to locoregional recurrences.

Authors:  Matahi Moarii; Alice Pinheiro; Brigitte Sigal-Zafrani; Alain Fourquet; Martial Caly; Nicolas Servant; Véronique Stoven; Jean-Philippe Vert; Fabien Reyal
Journal:  PLoS One       Date:  2014-08-06       Impact factor: 3.240

10.  Expression and DNA methylation of TNF, IFNG and FOXP3 in colorectal cancer and their prognostic significance.

Authors:  S K Ganapathi; A D Beggs; S V Hodgson; D Kumar
Journal:  Br J Cancer       Date:  2014-09-16       Impact factor: 7.640

View more
  1 in total

1.  Lysine demethylase 2A promotes stemness and angiogenesis of breast cancer by upregulating Jagged1.

Authors:  Jing-Yi Chen; Chien-Feng Li; Pei-Yi Chu; You-Syuan Lai; Chung-Hsing Chen; Shih Sheng Jiang; Ming-Feng Hou; Wen-Chun Hung
Journal:  Oncotarget       Date:  2016-05-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.